IDEAYA Biosciences (IDYA) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precigen (PGEN) has outperformed IDEAYA Biosciences (IDYA) over the past year, gaining 136.0% versus a gain of 34.4%. Over five years, PGEN leads with a +63.4% price change compared with +55.9% for IDYA. IDEAYA Biosciences is the larger company by market cap ($3.50 billion vs $2.77 billion), about 1.3 times the size.
IDEAYA Biosciences converts more of its revenue into profit, with a net margin of -52.0% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDYA | PGEN |
|---|---|---|
| Share price | $36.28 | $7.74 |
| Market cap | $3.50B | $2.77B |
| 1-day change | +0.61% | +1.78% |
| YTD return | +4.31% | +81.82% |
| 1-year return | +34.35% | +136.02% |
| 5-year return | +55.90% | +63.44% |
| EPS (TTM) | $-1.94 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $218.71M | $9.68M |
| Revenue growth (YoY) | +3024.43% | +146.73% |
| Net income (latest FY) | $-113.70M | $-250.64M |
| Operating margin | -72.84% | -1141.13% |
| Net margin | -51.99% | -2588.21% |
| 52-week high | $42.68 | $8.98 |
| 52-week low | $26.05 | $2.99 |
| Distance from 52-week high | -15.00% | -13.86% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +45.40% | +76.47% |
| Average volume | 779.15K | 5.03M |
| Shares outstanding | 96.49M | 358.04M |
| Employees | 145 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed IDYA by 101.7 percentage points over the past year.
- IDEAYA Biosciences is more profitable, keeping -52.0 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- IDEAYA Biosciences grew revenue faster in its latest fiscal year (+3024.43% vs +146.73%).
About IDEAYA Biosciences
IDYA stock →IDEAYA Biosciences, Inc., a precision medicine oncology company, develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and selective protein kinase, C (PKC) inhibitor for the treatment of uveal melanoma, ocular cancer, and is being evaluated in multiple clinical trials as monotherapy and in combination with crizotinib for metastatic, neoadjuvant, and adjuvant settings.
Health Care · Biotechnology: Pharmaceutical Preparations · 145 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Health Care · Biotechnology: Pharmaceutical Preparations · 160 employees
IDYA vs PGEN FAQ
Which is bigger, IDEAYA Biosciences or Precigen?
IDEAYA Biosciences (IDYA) is larger, with a market capitalization of $3.50B compared with $2.77B for Precigen (PGEN).
Which stock has performed better over the past year, IDYA or PGEN?
PGEN returned +136.02% over the past 12 months, compared with +34.35% for IDYA (price return, excluding dividends). Past performance does not predict future results.
Are IDEAYA Biosciences and Precigen in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.